IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

Core Insights - IN8bio has promoted Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately, to enhance leadership during a critical growth phase [1][2] Company Overview - IN8bio is a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases [1][6] - The company's lead program, INB-100, targets acute myeloid leukemia, while other programs include INB-200 and INB-400 for glioblastoma, and INB-600 for oncology and autoimmune indications [6] Leadership and Experience - Dr. Rochlin has over 17 years of experience in biotechnology, including roles in scientific research, intellectual property, business development, and clinical manufacturing [3] - Prior to her role at IN8bio, she served as Chief Business Officer at Curadigm, contributing to the company's spin-out from Nanobiotix [3] Clinical Advancements - Under Dr. Rochlin's leadership, IN8bio has advanced its clinical programs, including the development of INB-619, which has shown promising preclinical results in achieving complete B cell depletion with minimal adverse effects [4] - The company has made significant progress in its clinical manufacturing program, supporting multiple Phase 1 and 2 clinical trials in glioblastoma and hematological cancers [4] Future Outlook - Dr. Rochlin expressed confidence in the company's position to build on momentum from encouraging clinical data and aims to execute corporate priorities for long-term success [5]